About scPharmaceuticals Inc.

scPharmaceuticals Inc., founded in 2013, is pioneering the development of subcutaneous therapies that can transform hospital-based treatments into convenient outpatient administration. The company's lead product, FUROSCIX, represents the first FDA-approved subcutaneous loop diuretic for heart failure treatment outside hospital settings. SCPH stock price reflects both the commercial launch progress and the transformative potential of subcutaneous delivery for acute care.

Led by CEO John Tucker, scPharmaceuticals has successfully navigated the complex path from development through FDA approval to commercial launch. The management team brings extensive pharmaceutical industry experience in both development and commercialization. Leadership's strategic focus on building the infrastructure for FUROSCIX commercialization while advancing pipeline programs has been important for creating value and influencing SCPH stock price trajectory.

scPharmaceuticals operates by developing proprietary subcutaneous formulations of existing drugs, enabling self-administration for conditions typically requiring hospital treatment. The company's technology platform addresses the growing need for home-based care options that reduce healthcare costs while improving patient convenience. With FUROSCIX addressing a large heart failure market, healthcare systems seeking cost-effective alternatives to hospitalization, and pipeline opportunities in other acute conditions, SCPH offers investors exposure to innovative drug delivery addressing healthcare transformation, though commercial execution and market adoption remain key risks for this emerging company.